Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc. (BIO) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for Bio-Rad Laboratories, Inc. (BIO), covering cash flow, earnings, and balance sheets.
Bio-Rad Laboratories, Inc. (BIO) Income Statement & Financial Overview
Access detailed annual and quarterly income data for Bio-Rad Laboratories, Inc. BIO financial performance.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $585.40M | $667.48M | $649.73M | $638.48M |
| Cost of Revenue | $279.40M | $325.56M | $293.83M | $282.76M |
| Gross Profit | $306.00M | $341.91M | $355.90M | $355.12M |
| Gross Profit Ratio | $0.52 | $0.51 | $0.55 | $0.56 |
| R&D Expenses | $73.50M | $79.62M | $91.00M | $59.30M |
| SG&A Expenses | $208.80M | $204.00M | $200.44M | $196.12M |
| Operating Expenses | $282.30M | $283.58M | $291.44M | $253.62M |
| Total Costs & Expenses | $561.70M | $609.14M | $585.26M | $538.18M |
| Interest Income | $36.20M | $15.90M | $15.50M | $16.60M |
| Interest Expense | $12.00M | $12.19M | $12.17M | $12.26M |
| Depreciation & Amortization | $38.10M | $49.30M | $49.10M | $46.60M |
| EBITDA | $133.50M | -$847.40M | $922.89M | -$2.73B |
| EBITDA Ratio | $0.23 | -$1.27 | $1.42 | -$4.27 |
| Operating Income | $23.70M | $58.33M | $64.47M | $101.50M |
| Operating Income Ratio | $0.04 | $0.09 | $0.10 | $0.16 |
| Other Income/Expenses (Net) | $59.70M | -$967.23M | $797.15M | -$2.89B |
| Income Before Tax | $83.40M | -$908.90M | $861.62M | -$2.79B |
| Income Before Tax Ratio | $0.14 | -$1.36 | $1.33 | -$4.36 |
| Income Tax Expense | $19.40M | -$193.10M | $208.45M | -$620.79M |
| Net Income | $64.00M | -$715.80M | $653.17M | -$2.17B |
| Net Income Ratio | $0.11 | -$1.07 | $1.005 | -$3.39 |
| EPS | $2.29 | -$25.57 | $23.37 | -$76.26 |
| Diluted EPS | $2.29 | -$25.57 | $23.34 | -$76.26 |
| Weighted Avg Shares Outstanding | $27.94M | $28.00M | $27.95M | $28.39M |
| Weighted Avg Shares Outstanding (Diluted) | $27.95M | $28.00M | $27.98M | $28.39M |
Over the past four quarters, Bio-Rad Laboratories, Inc. demonstrated steady revenue growth, increasing from $638.48M in Q2 2024 to $585.40M in Q1 2025. Operating income reached $23.70M in Q1 2025, maintaining a consistent 4% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at $133.50M, reflecting operational efficiency. Net income rose to $64.00M, with EPS at $2.29. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan